Relay Therapeutics is a precision oncology company that uses protein motion to develop cancer therapeutics. It was founded in 2016 by David E. Shaw, Dorothee Kern, Mark Murcko, and Matthew Jacobson. Relay Therapeutics started its initial public offering (IPO) on July 20th, 2020. Prior to that, the company raised funding until its Series C round, receiving financing from investors such as SoftBank, Foresite Capital, and Tavistock Group. Relay Therapeutics is headquartered in Cambridge, Massachusetts, United States.
Relay Therapeutics has its own proprietary drug development platform called Dynamo, which integrates long-timescale molecular dynamics simulations and machine learning together with room-temperature crystallography and cryoEM. Dynamo also utilizes an approach that Relay Therapeutics called as motion-based drug design (MBDD), which is a form of drug discovery process that allows for long-timescale simulations of protein dynamics. Through these techniques and existing genome data, Relay Therapeutics is able to develop compounds that target specific genes, with recently developed drugs aimed at SHP-2, FGFR2, and PI3Kα.